tg
therapeutics
highlights
data
selected
presentation
american
society
hematology
ash
annual
meeting
significantly
improved
survival
obinutuzimab
plus
chlorambucil
p
well
orr
p
patients
cll
consistent
pfs
improvement
across
treatment
naïve
cll
relapsed
refractory
cll
umbralisib
monotherapy
demonstrated
orr
patients
relapsed
refractory
mzl
relapsed
refractory
fl
patients
plus
venetoclax
demonstrated
orr
umrd
peripheral
blood
umrd
bone
marrow
patients
relapsed
refractory
cll
cycle
therapy
btk
inhibitor
monotherapy
expansion
cohort
demonstrated
orr
patients
relapsed
refractory
cll
u
mbralisib
monotherapy
combination
across
abstract
trials
exhibited
manageable
safety
profile
low
incidence
toxicities
discontinuations
conference
call
leading
investigators
trials
held
tomorrow
november
et
new
york
globe
newswire
tg
therapeutics
nasdaq
tgtx
today
announced
release
four
abstracts
presented
upcoming
american
society
hematology
ash
annual
meeting
exposition
held
virtually
december
abstracts
publicly
available
online
via
ash
meeting
website
company
also
hosting
zoom
conference
call
tomorrow
november
et
leading
investigators
trials
abstract
highlights
conference
call
details
outlined
michael
weiss
executive
chairman
chief
executive
officer
stated
excited
share
first
data
pivotal
phase
trial
evaluating
combination
ublituximab
umbralisib
treatment
naïve
relapsed
refractory
cll
first
randomized
trial
inhibitor
treatment
naïve
cll
addition
equally
excited
present
updated
data
trial
supported
nda
umbralisib
updated
data
two
triple
therapy
datasets
including
plus
btk
inhibitor
plus
venetoclax
cll
importantly
believe
data
showcase
differentiated
tolerability
profile
umbralisib
daily
dual
inhibitor
potential
umbralisib
monotherapy
combination
fl
mzl
cll
look
forward
discussing
data
sets
tomorrow
call
leading
investigators
abstract
highlights
oral
presentation
title
umbralisib
plus
ublituximab
superior
obinutuzumab
plus
chlorambucil
patients
treatment
naïve
tn
relapsed
refractory
r
r
chronic
lymphocytic
leukemia
cll
results
phase
study
patients
randomized
arms
patients
r
r
cll
median
months
significantly
prolonged
survival
pfs
vs
median
months
vs
months
hazard
ratio
p
pfs
improvement
vs
consistent
across
subgroups
examined
including
treatment
naïve
patients
median
months
vs
months
hazard
ratio
relapsed
refractory
patients
median
months
vs
months
hazard
ratio
overall
response
rate
orr
significantly
higher
compared
vs
p
grade
adverse
events
ae
interest
regardless
causality
vs
included
neutropenia
vs
thrombocytopenia
vs
diarrhea
vs
infusion
related
reaction
vs
elevated
ast
alts
vs
colitis
vs
pneumonitis
vs
conclusion
exhibited
safety
profile
significantly
improved
pfs
standard
care
chemoimmunotherapy
patients
treatment
naïve
relapsed
refractory
cll
poster
presentation
title
umbralisib
daily
dual
inhibitor
casein
demonstrates
clinical
activity
patients
relapsed
refractory
indolent
lymphoma
results
phase
global
trial
total
patients
inhl
received
least
dose
umbralisib
including
marginal
zone
lymphoma
mzl
follicular
lymphoma
fl
small
lymphocytic
lymphoma
sll
patients
mzl
patients
relapsed
refractory
prior
lines
treatment
including
median
follow
months
following
observed
orr
complete
response
cr
rate
median
pfs
reached
estimated
pfs
rate
patients
achieved
cr
experienced
disease
progression
date
fl
patients
relapsed
refractory
prior
lines
including
alkylating
agent
median
follow
months
following
observed
orr
achieving
cr
median
pfs
months
estimated
pfs
rate
common
aes
grade
neutropenia
diarrhea
increased
alt
ast
aes
interest
included
pneumonitis
grades
grade
colitis
grades
grade
conclusion
umbralisib
achieved
meaningful
clinical
activity
heavily
pretreated
inhl
population
safety
profile
manageable
relatively
low
incidence
toxicities
discontinuations
poster
presentation
title
phase
study
umbralisib
ublituximab
venetoclax
patients
relapsed
refractory
chronic
lymphocytic
leukemia
cll
regimen
administered
cycles
followed
umbralisib
plus
venetoclax
cycles
patients
undetectable
minimal
residual
disease
umrd
bone
marrow
cycle
permitted
stop
therapy
mrd
detectable
patients
continued
single
agent
umbralisib
patients
treated
data
cutoff
among
evaluable
patients
orr
cycle
cycle
cycle
among
patients
finished
cycles
therapy
achieved
complete
response
cr
iwcll
criteria
achieved
undetectable
mrd
peripheral
blood
achieved
undetectable
mrd
bone
marrow
grade
aes
occurring
patients
neutropenia
leukopenia
infusion
related
reactions
tls
events
observed
venetoclax
administration
conclusion
results
suggest
regimen
provide
undetectable
mrd
cycles
treatment
representing
effective
treatment
option
population
poster
presentation
title
clinical
activity
monotherapy
combination
ublituximab
umbralisib
patients
malignancies
total
patients
treated
patients
receiving
monotherapy
cohort
cohort
combination
dose
escalation
cohort
monotherapy
well
tolerated
maximum
tolerated
dose
reached
mg
qd
common
grade
adverse
events
trae
neutropenia
monotherapy
neutropenia
alt
ast
increases
trae
monotherapy
median
follow
months
mg
qd
monotherapy
expansion
cohorts
preliminary
overall
response
rates
orr
cll
mcl
wm
orr
patients
wm
cll
mzl
dlbcl
fl
abstracts
publicly
available
via
ash
meeting
website
also
accessible
via
publications
page
tg
corporate
website
http
confer
ence
call
information
company
hosting
zoom
conference
call
tomorrow
november
begin
et
order
participate
call
please
join
via
zoom
webinar
link
https
also
available
events
page
located
within
investors
media
section
company
website
https
events
attendees
may
also
join
via
phone
dialing
outside
conference
title
tg
therapeutics
ash
abstract
review
call
recording
conference
call
also
available
replay
period
days
call
tg
therapeutics
tg
therapeutics
biopharmaceutical
company
focused
acquisition
development
commercialization
novel
treatments
malignancies
autoimmune
diseases
currently
company
late
stage
clinical
development
two
investigational
compounds
ublituximab
umbralisib
combination
referred
targeting
hematological
malignancies
autoimmune
diseases
ublituximab
glycoengineered
monoclonal
antibody
targets
specific
unique
epitope
antigen
found
mature
umbralisib
oral
dual
inhibitor
umbralisib
currently
review
food
drug
administration
fda
accelerated
approval
treatment
patients
previously
treated
marginal
zone
lymphoma
mzl
received
least
one
prior
based
regimen
follicular
lymphoma
fl
received
least
two
prior
systemic
therapies
company
also
fully
enrolled
phase
clinical
trial
evaluating
patients
treatment
naïve
relapsed
refractory
chronic
lymphocytic
leukemia
cll
two
fully
enrolled
identical
phase
trials
evaluating
ublituximab
monotherapy
patients
relapsing
forms
multiple
sclerosis
rms
additionally
company
recently
brought
phase
clinical
development
monoclonal
antibody
cosibelimab
bruton
tyrosine
kinase
btk
inhibitor
well
bispecific
antibody
tg
therapeutics
headquartered
new
york
city
cautionary
statement
press
release
contains
statements
involve
number
risks
uncertainties
statements
claim
protection
safe
harbor
statements
contained
private
securities
litigation
reform
act
addition
risk
factors
identified
time
time
reports
filed
securities
exchange
commission
factors
could
cause
actual
results
differ
materially
include
following
risk
results
trial
sufficient
acceptable
support
regulatory
submission
combination
ublituximab
umbralisib
treatment
cll
risk
results
trial
previously
treated
fl
mzl
sufficient
support
accelerated
approval
pending
nda
umbralisib
risk
able
meet
regulatory
submission
timelines
project
achieve
anticipated
milestones
including
risk
evolving
unpredictable
pandemic
delays
achievement
milestones
risk
interim
early
clinical
trial
results
may
supported
acceptance
data
presentation
influenced
decision
proceed
additional
clinical
trials
reproduced
final
data
sets
future
studies
risk
safety
profile
observed
umbralisib
ublituximab
combinations
thereof
may
change
additional
patients
exposed
longer
durations
risk
combination
prove
safe
efficacious
combination
backbone
triple
therapy
combinations
including
venetoclax
statements
set
forth
press
release
speak
date
press
release
undertake
update
statements
reflect
events
circumstances
occur
date
hereof
press
release
prior
releases
available
information
found
website
incorporated
reference
press
release
included
reference
purposes
